文献速递腹部USCTMR

LI-RADS CEUS 非辐射治疗反应评估版本2024:在消融治疗的肝细胞癌患者中的应用

LI-RADS CEUS Nonradiation TRA Version 2024: Application on HCC Patients Treated With Ablation Treatment.
PubMed 文献 · Ultrasound Med Biol · 2025-05-20

本研究前瞻性收集2020年6月至2022年12月肝细胞癌患者标准化CEUS数据,回顾性分析2名独立放射科医师按LI-RADS CEUS非辐射TRA v2024对病灶进行TR-nonviable、TR-equivocal或TR-viable分类。共纳入83例患者88个病灶的101次CEUS-LI-RADS TRA分类评估。结果显示观察者间一致性为中等至几乎完美,CEUS与CT/MRI LI-RADS TRA分类间一致性优秀(ICC=0.90),CEUS LR-TRA分类诊断性能良好,尤其特异度(88.1%-100%)和阴性预测值(93.9%-97.9%)。

要点

  • CEUS LI-RADS Nonradiation TRA v2024在消融后HCC病灶评估中观察者间一致性中等至几乎完美。
  • CEUS与CT/MRI LI-RADS TRA分类间一致性优秀(ICC=0.90)。
  • CEUS LR-TRA分类特异度88.1%-100%,阴性预测值93.9%-97.9%。

核心结论

  • LI-RADS CEUS Nonradiation TRA v2024表现出良好的观察者间和模态间一致性,诊断性能优异,支持其在评估消融后HCC治疗反应中的临床应用潜力。

研究设计与样本

  • 前瞻性收集2020年6月至2022年12月HCC患者标准化CEUS数据,回顾性分析2名独立放射科医师对83例患者88个病灶的101次CEUS-LI-RADS TRA分类评估,并与CT/MRI LI-RADS TRA进行模态间比较。

诊断标准与关键数值

  • CEUS LR-TRA分类包括TR-nonviable、TR-equivocal和TR-viable;观察者间一致性:病灶内肿瘤活性κ=0.92(95%CI:0.76-1.0),病灶周围肿瘤活性κ=0.72(95%CI:0.57-0.87),CEUS LR-TR κ=0.71(95%CI:0.55-0.88);CEUS与CT/MRI LI-RADS TRA分类间ICC=0.90;特异度88.1%-100%,阴性预测值93.9%-97.9%。

临床应用与阅片要点

  • LI-RADS CEUS Nonradiation TRA v2024可用于消融后HCC治疗反应评估,观察者间和模态间一致性良好;时间阶段和抽象形状是影响读者评估的显著因素(p<0.05)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the performance of Liver Imaging Reporting and Data System (LI-RADS) contrast-enhanced ultrasound (CEUS) Nonradiation treatment response assessment (TRA) categorization v2024 for detecting viable tumors of ablated hepatocellular carcinoma (HCC).

METHODS: Between June 2020 and December 2022, standardized CEUS data of HCC patients were prospectively collected. A retrospective analysis of LI-RADS CEUS Nonradiation TRA v2024 evaluation on HCCs was conducted by 2 independent radiologists assigning per-lesion TRA (TR-nonviable, TR-equivocal, or TR-viable) categorizations. Inter-reader agreement between the 2 readers and inter-modality agreement between LI-RADS CEUS and CT/MRI LI-RADS TRA were assessed. The diagnostic performance of imaging criteria was explored. The potential influencing factors of LI-RADS TRA categorization across modalities were further analyzed.

RESULTS: A total of 101 CEUS-LI-RADS TRA category evaluations of 88 lesions in 83 patients were included. Inter-reader agreement for the 2 readers were substantial to almost perfect (intralesional tumor viability: κ = 0.92, 95% CI: 0.76-1.0; perilesional tumor viability: κ = 0.72, 95% CI: 0.57-0.87; CEUS LR-TR: κ = 0.71, 95% CI: 0.55-0.88). Inter-modality agreements between CEUS and CT/MRI LI-RADS TRA categorizations were excellent (ICC = 0.90). CEUS LR-TRA categorization demonstrated good diagnostic performance, particularly in specificity (88.1%-100 %) and negative predictive value (NPV: 93.9%-97.9 %). Time period and abstract shape were identified as significant factors influencing reader evaluations (p < 0.05).

CONCLUSION: LI-RADS CEUS Nonradiation TRA v2024 demonstrates fine inter-reader and inter-modality agreement, with outstanding diagnostic performance, supporting its potential for clinical application in assessing treatment response for ablated HCC.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Cao J, Dong Y, Xu X, et al. LI-RADS CEUS Nonradiation TRA Version 2024: Application on HCC Patients Treated With Ablation Treatment. Ultrasound Med Biol. 2025. PMID: 40399228. doi:10.1016/j.ultrasmedbio.2025.04.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。